Methoxphenidine is a novel dissociative designer drug of the diarylethylamine class which shares structural features with phencyclidine (PCP), and is not at present subject to restrictive regulations. There is very limited information about the acute toxicity profile of methoxphenidine and the only sources are anonymous internet sites and a 1989 patent of the Searle Company. We report a case of analytically confirmed oral methoxphenidine toxicity. CASE DETAILS: A 53-year-old man was found on the street in a somnolent and confusional state. Observed signs and symptoms such as tachycardia (112 bpm), hypertension (220/125 mmHg), echolalia, confusion, agitation, opisthotonus, nystagmus and amnesia were consistent with phencyclidine-induced adverse effects. Temperature (99.1°F (37.3°C)) and peripheral oxygen saturation while breathing room air (99%) were normal. Laboratory analysis revealed an increase of creatine kinase (max 865 U/L), alanine aminotransferase (72 U/L) and gamma-glutamyl transpeptidase (123 U/L). Methoxphenidine was identified by a liquid chromatography tandem mass spectrometry toxicological screening method using turbulent flow online extraction in plasma and urine samples collected on admission. The clinical course was favourable and signs and symptoms resolved with symptomatic treatment. CONCLUSION: Based on this case report and users' web reports, and compatible with the chemical structure, methoxphenidine produces effects similar to those of the arylcyclohexylamines, as PCP. 
Abstract
Introduction: Methoxphenidine is a novel dissociative designer drug of the diarylethylamine class which shares structural features with phencyclidine (PCP), and is not at present subject to restrictive regulations. There is very limited information about the acute toxicity profile of methoxphenidine and the only sources are anonymous internet sites and a 1989 patent of the Searle company. We report a case of analytically confirmed oral methoxphenidine toxicity.
Case details: A 53-year-old man was found on the street in a somnolent and confusional state. Observed signs and symptoms such as tachycardia (112 bpm), hypertension (220/125 mmHg), echolalia, confusion, agitation, opisthotonus, nystagmus, and amnesia were consistent with phencyclidine-induced adverse effects. Temperature (99.1 °F, 37.3°C) and peripheral oxygen saturation while breathing room air (99%) were normal. Laboratory analysis revealed an increase of creatine kinase (max 865 U/L), alanine aminotransferase (72 U/L), and gammaglutamyl transpeptidase (123 U/L). Methoxphenidine was identified by a liquid chromatography tandem mass spectrometry toxicological screening method using turbulent flow online extraction in plasma and urine samples collected on admission.
The clinical course was favourable and signs and symptoms resolved with symptomatic treatment.
Conclusion:
Based on this case report and users' web reports, and compatible with the chemical structure, methoxphenidine produces effects similar to those of the arylcyclohexylamines, as PCP.
, is a diarylethylamine compound that shares structural features with the arylcyclohexylamines, such as phencyclidine (PCP), ketamine, and methoxetamine (MXE), and with the diarylethylamine diphenidine ( Figure 1 ). 1 These recreational psychoactive substances with dissociative effects are highly addictive because of their ability to produce intense psychedelic effects. 1 Shortly after the 2013 UK ban on arylcyclohexylamines, methoxphenidine became available on the grey market. 1 It is advertised and sold through the internet as a research chemical in form of a white powder or crystals. Methoxphenidine, which possesses a lower affinity for N-methyl-D-aspartate (NMDA) receptors than the related compound diphenidine, was first reported in a 1989 patent as a potential treatment for neurotoxic injury. 2 As a consequence of structural similarity, the effects of methoxphenidine might be assumed to be similar to those of other dissociative drugs. 1 There is no reliable information on the pharmacology, effects and toxicity of this substance, and established analytical methods are lacking. The only sources of information are drug users' web discussion forums, in which euphoria, feeling of happiness, stimulating effects, disorientation, dissociative effects (starting at 80 mg methoxphenidine), and transient anterograde amnesia lasting for 3-6 h are mentioned. Some users report undesired effects including tachycardia, hyperthermia, panic attacks, and, after ingestion of higher doses, seizures requiring hospitalisation. 1 Methoxphenidine is generally used orally, in doses of 80-150 mg (in some reports up to 500 mg), and users report a steep dose-response curve. 3,4 Effects are described to begin after 60 min, with a duration up to 18 h. 4 We report a case of acute toxicity after oral methoxphenidine use confirmed by the identification of the substance and its metabolites in serum and urine by a liquid chromatography tandem mass spectrometry toxicological screening method.
Case report
A 53-year-old Caucasian male with a history of diabetes mellitus and multiple Methoxphenidine was identified in the plasma as well as in the urine sample ( Figure   2 ). In the urine sample, the following methoxphenidine metabolites were identified in addition to the parent compound: three different hydroxylation products, the product of O-demethylation, and three different glucuronidated hydroxylation products.
Furthermore, trace amounts of benzoylecgonine, amlodipine and metabolite, buprenorphine and metabolite, norfentanyl, hydrochlorothiazide, metformin, lidocaine and metabolite, as well as nicotine and metabolite were detected. In the plasma, in addition to methoxphenidine, lorazepam, lidocaine and metabolite, and amlodipine were detected.
Discussion
Dissociative drugs including PCP and ketamine are used recreationally for their mindaltering effects. Starting with the first dissociative designer drug, 4-MeO-PCP in 2008, the dissociative designer drug market has rapidly evolved, and several of these compounds have reached widespread use internationally. 1 This is true for MXE, which has therefore been scheduled in recent years as a controlled substance in many countries. Drug-selling sites now specifically promote methoxphenidine as a legal replacement for the banned arylcyclohexylamines such as MXE and 4-MeO-PCP. Methoxphenidine seems to be rapidly gaining popularity, and forum posts on this compound are steadily increasing. Concomitantly to the appearance of methoxphenidine on the grey market, diphenidine, another dissociative designer drug of the diarylethylamine class with a very close chemical structure and similar effects to methoxphenidine, emerged. As is usually the case for novel psychoactive substances, also for the arylcyclohexylamines and diarylethylamines, little is known about their health risks when they enter the recreational drug scene.
Methoxphenidine users describe the effects as similar to those of ketamine and MXE. 6,3 Actually, signs and symptoms observed in our patient such as hypertension, tachycardia, confusion, sedation, shifts in perception of reality, agitation, nystagmus, opisthotonus, amnesia, and urinary retention are compatible with the effects induced by MXE, ketamine, and PCP. 7, 8, 9 Moreover, speech disorders such as pressured speech, verbigerations, and echolalia have been regularly reported by users of PCP and ketamine. 8, 9 Hypertension and nystagmus, which were observed in our patient, are hallmarks of PCP intoxication, and both have been reported to occur in about 57% of the cases and to resolve within 4 h of PCP consumption. 9 Also miosis is common in PCP intoxication 12 and was observed in our patient. A major contribution by buprenorphine seems unlikely as the patient had no respiratory depression and showed a rapid resolution of the central nervous system depression.
The initial neurological presentation of our patient with loss of consciousness associated with opisthotonus is compatible with a tonic seizure. Seizures have been reported after use of PCP 9 and also rarely by MXP users. 1, 3 Furthermore, the analgesic drug lefetamine, which is structurally related to methoxphenidine and which was abused in Japan and Europe and has been withdrawn from the market, has been reported to cause seizures in rats. 10 In our patient, all detected substances other than methoxphenidine, norfentanyl, and benzylecgonine (i.e. buprenorphine, amlodipine, candesartan, dihydrochlorothiazide, metformin, lorazepam, and lidocaine) were used therapeutically. Norfentanyl and traces of benzoylecgonine slightly above the detection limit in absence of the parent compounds were found in the urine sample only, and this is compatible with the 7 prolonged detectability (up to 72 hours) of norfentanyl, the major metabolite of fentanyl, 11 and benzoylecgonine. 12 We are therefore persuaded that there is enough evidence to reject the hypothesis of a simultaneous abuse of fentanyl and/or cocaine, which could have influenced the clinical course.
Because methoxphenidine is at present not subject to restrictive regulations, it seems plausible that the consumption of this substance might increase internationally. For this reason, further studies are needed to determine the pharmacological and toxicological properties of methoxphenidine, and to analyse patterns of acute toxicity in humans and possible long-term effects, including neuropsychiatric disorders as well as urinary bladder, liver, and brain injury, which were observed after long-term abuse of PCP and ketamine. 13, 14, 15 In conclusion, methoxphenidine appears to have a similar acute toxicity profile to other arylcyclohexylamines, such as PCP, ketamine, and MXE. On the basis of the very limited evidence available, management of patients presenting with acute toxicity related to methoxphenidine use should be as for other dissociative drugs.
Patient's consent
A document showing the patient's written consent to this publication is available on request.
